Jiangsu Hengrui Medicine Co., Ltd

🇨🇳China

Country: 🇨🇳China

Ownership: -

Established: 1970-01-01

Employees: -

Market Cap: $38.9B

Website: http://www.hrs.com.cn/english/

Clinical Trials

Study of Apatinib After Systemic Therapy in Patients With Hepatocellular Carcinoma(AHELP)

Phase 3

Completed

Conditions: Carcinoma, Hepatocellular

Interventions: Drug: Placebo
Drug: Apatinib

First Posted Date: 2015-01-01

Last Posted Date: 2024-01-22

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 400

Registration Number: NCT02329860

Locations: 🇨🇳
Jiangsu hengrui medicine CO. LTD, Lianyungang, Jiangsu, China

Clinical Trial of Systolic Heart Failure Treatment of IvabRadine Hemisulfate Sustained-release Tablets （FIRST）

Phase 2

Conditions: Chronic Systolic Heart Failure

Interventions: Drug: IvabRadine hemisulfate Sustained-release Tablets
Drug: placebo

First Posted Date: 2014-07-11

Last Posted Date: 2014-07-11

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 336

Registration Number: NCT02188082

Locations: 🇨🇳
Subei People's Hospital of Jiangsu province, Yangzhou, Jiangsu, China
🇨🇳
the Second Hospital of Shandong University, Jinan, Shandong, China
🇨🇳
The second affiliated hospital of wenzhou medical university, Wenzhou, Zhejiang, China

and more 9 locations

A Phase II Study Comparing Pegylated rhG-CSF（HHPG-19K） and rhG-CSF in Breast Cancer Patients Receiving Chemotherapy

Phase 2

Completed

Conditions: Febrile Neutropenia
Breast Cancer
Neutropenia

Interventions: Drug: Pegylated rhG-CSF 100μg/kg
Drug: rhG-CSF 5 μg/kg/day

First Posted Date: 2014-04-22

Last Posted Date: 2014-04-22

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 182

Registration Number: NCT02119715

Locations: 🇨🇳
307 Hospital Affiliated to Academy Military Medical Science, Beijing, China

A Phase Ⅲ Study of Extended-Release Carvedilol Sulfate for the Treatment of Heart Failure

Phase 3

Conditions: Heart Failure

Interventions: Drug: Sustained-release Metoprolol Succinate
Drug: Extended-Release Carvedilol Sulfate

First Posted Date: 2013-12-16

Last Posted Date: 2013-12-16

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 316

Registration Number: NCT02012075

Locations: 🇨🇳
Gansu Provincial Hospital, Lanzhou, Gansu, China
🇨🇳
Tongji Hospital, Wuhan, Hubei, China
🇨🇳
The Second Xiangya Hospital of Central South University, Changsha, Hunan, China

and more 9 locations

A Study of Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumor

Phase 2

Terminated

Conditions: Gastroenteropancreatic Neuroendocrine Tumor

Interventions: Drug: Famitinib

First Posted Date: 2013-11-25

Last Posted Date: 2019-01-22

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 53

Registration Number: NCT01994213

Locations: 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China

A Phase 4 Study of Imrecoxib in Treatment of Knee Osteoarthritis

Phase 4

Conditions: Knee Osteoarthritis

Interventions: Drug: Imrecoxib

First Posted Date: 2013-11-15

Last Posted Date: 2013-11-15

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 2400

Registration Number: NCT01985165

Locations: 🇨🇳
Shengjing Hospital of China Medical University, Shenyang, Liaoning, China
🇨🇳
The Second Hospital of Shangdong University, Jinan, Shandong, China
🇨🇳
Taizhou Hospital, Taizhou, Zhejiang, China

and more 16 locations

Efficacy and Safety Study of SHR117887 in Combination With Metformin in Patients With Type 2 Diabetes

Phase 2

Completed

Conditions: Type 2 Diabetes

Interventions: Drug: Placebo
Drug: SHR117887

First Posted Date: 2013-11-14

Last Posted Date: 2013-11-19

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 120

Registration Number: NCT01984489

A Phase I Study of 8-week Continuous Treatment With Polyethylene Glycol Loxenatide in Patients With Type 2 Diabetes

Phase 1

Completed

Conditions: Type 2 Diabetes

Interventions: Drug: PEX168

First Posted Date: 2013-11-06

Last Posted Date: 2013-11-06

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 50

Registration Number: NCT01976858

Locations: 🇨🇳
Beijing tongren hospital, Beijing, Beijing, China

A Study of the Effectiveness and Safety of SP2086 to Treat Type 2 Diabetes

Phase 2

Completed

Conditions: Type 2 Diabetes

Interventions: Drug: 100 mg Sitagliptin
Drug: Placebo
Drug: 50 mg SP2086
Drug: 100 mg SP2086
Drug: 200 mg SP2086

First Posted Date: 2013-10-25

Last Posted Date: 2013-10-25

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 200

Registration Number: NCT01969357

Locations: 🇨🇳
Chinese PLA General Hospital, Beijing, China

A Phase III Study of SP2086 in Combination With Metformin in Patients With Type 2 Diabetes

Phase 3

Conditions: Type 2 Diabetes

Interventions: Drug: SP2086 50 mg q.d./Metformin
Drug: SP2086 50 mg b.i.d/Metformin
Drug: Placebo/Metformin

First Posted Date: 2013-10-25

Last Posted Date: 2013-10-25

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 360

Registration Number: NCT01970046

Locations: 🇨🇳
Chinese PLA General Hospital, Beijing, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy